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Intravitreal  triamcinolone acetonide (IVTA) has been shown to improve visual acuity 
(VA) and reduce  central macular thickness (CMT) in different pathologies 
 
IVTA is associated with a low incidence of surgical complications but with some well-
known  side effects (increase in intraocular pressure, cataract development) 
 
The recurrence of edema is related to the disappearance of triamcinolone from the 
vitreous: a mean elimination half-life of 18.6 days has been described and it was 
estimated that 4 mg of triamcinolone would last in the vitreous for approximately 3 
months. 
 
In theory, the half-life of this drug should be smaller in previously vitrectomized eyes  





To analyse the effect of IVTA on CMT in previously vitrectomized eyes.  
     
METHODS 
Retrospective study, Hospital de Braga, Ophthalmology Department 
Eyes with macular edema that had previously underwent 23G pars plana vitrectomy. 
 
The following parameters were analyzed before and after IVTA: 
•  Best Corrected Visual Acuity (BCVA),  
•  Intra-ocular Pressure (IOP), 
•  Mean CMT using Optical Coherence Tomography (Cirrus HD-OCT Zeiss®). 
We compared the change in mean CMT and its duration over time.  




11 pseudophakic eyes of 9 patients were included as shown below. 
 
Age (years) 






Right Eye 6 
Left Eye 5 
Mean time 
between PPV and 
IVTA (months) 
Mean (±SD) 11.12 (±4.5) 
Range 2.3 – 14.8 
Cause 
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Patient 
CMT before and after IVTA per patient Before IVTA After 1st IVTA 
After 2nd IVTA 
6 
CMT reduction lasted a mean (±SD) of 11.62±3.46 weeks.  
CONCLUSIONS 
Triamcinolone should be considered in the treatment of patients with persistent macular 
edema in vitrectomized eyes. CMT lowering effect of triamcinolone in vitrectomized eyes 
approached the time-range of 12 to 14 weeks usually seen in non-vitrectomized eyes.  
